Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 20(r)-ginsenoside Rg(3)
2. 20(s)-ginsenoside Rg(3)
3. 20s-ginsenoside Rg3
4. 3-o-beta-d-glucopyranosyl-(1->2)-beta-d-glucopyranosyldammar-24-ene-3beta,12beta,20s-triol
5. Beta-d-glucopyranoside, (3beta,12beta)-12,20-dihydroxydammar-24-en-3-yl 2-o-beta-d-glucopyranosyl-
6. Ginsenoside 20-rg3
7. Ginsenoside Rg(3)
8. Ginsenoside Rg3, (+)-
9. Ginsenoside Rg3, (s)-
10. S-ginsenoside Rg3
1. 14197-60-5
2. 20s-ginsenoside Rg3
3. (20s)-propanaxadiol
4. 20s-propanaxadiol
5. (20s)-ginsenoside Rg3
6. S-ginsenoside Rg3
7. 20(s)-ginsenoside Rg3
8. 20(s)-ginsenoside-rg3
9. 20(s)-propanaxidiol
10. Chembl398412
11. Chebi:67991
12. (2s,3r,4s,5s,6r)-2-[(2r,3r,4s,5s,6r)-4,5-dihydroxy-2-[[(3s,5r,8r,9r,10r,12r,13r,14r,17s)-12-hydroxy-17-[(2s)-2-hydroxy-6-methylhept-5-en-2-yl]-4,4,8,10,14-pentamethyl-2,3,5,6,7,9,11,12,13,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-6-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol
13. 11019-45-7
14. 227d367y57
15. (r)ginsenoside-rg3
16. Ginsenoside 20-rg3
17. Ginsenoside Rg3, (s)-
18. Ginsenoside Rg3, (+)-
19. Unii-227d367y57
20. Rg3
21. Mfcd06410950
22. Ginsenoside Rg3,(s)
23. 2'(r)-ginsenoside-rg3
24. Gtpl7658
25. Ginsenoside Rg3 [who-dd]
26. Dtxsid101316982
27. Hms3886b14
28. Bdbm50317537
29. Ginsenoside Rg3, Analytical Standard
30. S9022
31. Zinc96085900
32. Ginsenoside Rg3, >=98% (hplc)
33. Akos037514674
34. Ccg-270472
35. (3beta,12beta)-12,20-dihydroxydammar-24-en-3-yl 2-o-beta-d-glucopyranosyl-beta-d-glucopyranoside
36. As-56617
37. Dammar-24-ene-12-beta,20-diol, 3-beta-((2-o-beta-d-glucopyranosyl-beta-d-glucopyransoyl)oxy)-
38. C20778
39. 197g605
40. Q-100154
41. Q27077807
42. .beta.-d-glucopyranoside, (3.beta.,12.beta.)-12,20-dihydroxydammar-24-en-3-yl 2-o-.beta.-d-glucopyranosyl-
43. 3-o-.beta.-d-glucopyranosyl-(1->2)-.beta.-d-glucopyranosyldammar-24-ene-3.beta.,12.beta.,20s-triol
44. Beta-d-glucopyranoside, (3-beta,12-beta)-12,20-dihydroxydammar-24-en-3-yl 2-o-beta-d-glucopyranosyl-
45. Dammar-24-ene-12beta,20-diol, 3-beta-((2-o-beta-d-glucopyranosyl-beta-d-glucopyransoyl)oxy)-
| Molecular Weight | 785.0 g/mol |
|---|---|
| Molecular Formula | C42H72O13 |
| XLogP3 | 4 |
| Hydrogen Bond Donor Count | 9 |
| Hydrogen Bond Acceptor Count | 13 |
| Rotatable Bond Count | 10 |
| Exact Mass | 784.49729235 g/mol |
| Monoisotopic Mass | 784.49729235 g/mol |
| Topological Polar Surface Area | 219 Ų |
| Heavy Atom Count | 55 |
| Formal Charge | 0 |
| Complexity | 1370 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 20 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Antineoplastic Agents, Phytogenic
Agents obtained from higher plants that have demonstrable cytostatic or antineoplastic activity. (See all compounds classified as Antineoplastic Agents, Phytogenic.)
ABOUT THIS PAGE
A Ginsenoside Rg3 manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Ginsenoside Rg3, including repackagers and relabelers. The FDA regulates Ginsenoside Rg3 manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Ginsenoside Rg3 API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Ginsenoside Rg3 manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Ginsenoside Rg3 supplier is an individual or a company that provides Ginsenoside Rg3 active pharmaceutical ingredient (API) or Ginsenoside Rg3 finished formulations upon request. The Ginsenoside Rg3 suppliers may include Ginsenoside Rg3 API manufacturers, exporters, distributors and traders.
click here to find a list of Ginsenoside Rg3 suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Ginsenoside Rg3 as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Ginsenoside Rg3 API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Ginsenoside Rg3 as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Ginsenoside Rg3 and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Ginsenoside Rg3 NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Ginsenoside Rg3 suppliers with NDC on PharmaCompass.
Ginsenoside Rg3 Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Ginsenoside Rg3 GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Ginsenoside Rg3 GMP manufacturer or Ginsenoside Rg3 GMP API supplier for your needs.
A Ginsenoside Rg3 CoA (Certificate of Analysis) is a formal document that attests to Ginsenoside Rg3's compliance with Ginsenoside Rg3 specifications and serves as a tool for batch-level quality control.
Ginsenoside Rg3 CoA mostly includes findings from lab analyses of a specific batch. For each Ginsenoside Rg3 CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Ginsenoside Rg3 may be tested according to a variety of international standards, such as European Pharmacopoeia (Ginsenoside Rg3 EP), Ginsenoside Rg3 JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Ginsenoside Rg3 USP).
LOOKING FOR A SUPPLIER?
